-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex partners with Roche Diagnostics on NSCLC biomarker assay validation studies

PUBT·08/03/2026 11:01:15
Listen to the news
Genprex partners with Roche Diagnostics on NSCLC biomarker assay validation studies
  • Genprex entered a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer trials.
  • Work will focus on TROP2 scoring using Roche’s validated TROP2 antibody to align testing with Roche’s NSCLC diagnostic approach.
  • Genprex cited prior data linking TROP2 H-scores above 100 and PTEN H-scores below 100 to longer progression-free survival in NSCLC.
  • Validation studies are targeted for completion by end-2026, with potential integration into Genprex’s NSCLC clinical program thereafter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608030700PR_NEWS_USPR_____DA16806) on August 03, 2026, and is solely responsible for the information contained therein.